NCT07898683RecruitingPhase 1
A Phase I Study of Intra-Arterial Yttrium-90 Radioembolization for Unresectable Pancreatic Cancer
Selective Intra-Arterial Yttrium-90 Radioembolization for the Treatment of Unresectable Pancreatic Adenocarcinoma: A Phase I Clinical Trial
Source: ClinicalTrials.gov · Last updated 27 Oct 2026
Brief summary (registry, in English)
This clinical study aims to evaluate the safety and tolerability of intra-arterial Yttrium-90 (90Y) glass microspheres in patients with unresectable pancreatic adenocarcinoma. The study will assess radiation dose distribution, adverse effects, and preliminary efficacy following selective arterial radioembolization.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- First submitted
- 8 Oct 2026
- Start date
- 11 Feb 2025
- Primary completion date
- Dec 2027
- Lead sponsor
- National Medical Research Radiological Centre of the Ministry of Health of Russia
- Diseases
- Pancreatic cancer
- NCT number
- NCT07898683
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 12
- From 11 Feb 2025 to the primary completion date, Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior solid organ transplant
Other illness
- Active gastrointestinal ulcers or recent GI bleeding (\<3 months)
- Active Hepatitis B/C or other significant infectious disease
- Uncontrolled cardiovascular disease (NYHA class III/IV heart failure, recent MI, severe arrhythmias)
- Any condition deemed by investigators as unsafe for participation
Lab values
- Significant haematological abnormalities (ANC \<1.5×10⁹/L, platelets \<100×10⁹/L, haemoglobin \<8 g/dL)
- Severe hepatic dysfunction (total bilirubin \>1.5×ULN, ALT/AST \>4×ULN without liver metastases)
Other
- ECOG \>2 or Karnofsky score \<60%
- Pregnancy or lactation
Who the study is looking for
- Histologically confirmed pancreatic adenocarcinoma (T4N0/1M0/1)
- ECOG performance status 0-1, for at least 2 weeks
- Life expectancy ≥12 weeks
- Signed informed consent for participation
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Medical Radiological Research Center named after A.F. Tsyb (MRRC) - National Medical Research Center of Radiology Coordinator of this site? Confirm its status | Obninsk | Russia | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.